---
title: "JINGXIN has repurchased 4.08% of its shares, costing 443 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233853094.md"
description: "According to the Zhitong Finance APP, JINGXIN announced that as of March 31, 2025, the company repurchased 35.1 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 4.08% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 14.41 per share, the lowest transaction price was RMB 11.86 per share, and the total transaction amount was RMB 443 million (excluding transaction fees)"
datetime: "2025-03-31T09:19:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233853094.md)
  - [en](https://longbridge.com/en/news/233853094.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233853094.md)
---

# JINGXIN has repurchased 4.08% of its shares, costing 443 million yuan

According to the Zhitong Finance APP, JINGXIN (002020.SZ) announced that as of March 31, 2025, the company repurchased 35.1 million shares through a dedicated securities account for share repurchase via centralized bidding, accounting for 4.08% of the company's current total share capital. The highest transaction price for the repurchased shares was 14.41 yuan/share, the lowest transaction price was 11.86 yuan/share, and the total transaction amount was 443 million yuan (excluding transaction fees)

### Related Stocks

- [002020.CN](https://longbridge.com/en/quote/002020.CN.md)

## Related News & Research

- [Meliuz audit committee cuts stake by R$ 44,252 after cash share sales](https://longbridge.com/en/news/295452069.md)
- [FDA Issues Warning About Certain Products Containing Toxic Yellow Oleander](https://longbridge.com/en/news/295690341.md)
- [Physitrack Commences Share Buyback Program](https://longbridge.com/en/news/295383613.md)
- [Minnesota Democrats choose Peggy Flanagan as US Senate nominee, media project](https://longbridge.com/en/news/295609303.md)
- [SHUKRAPHAR: Strong revenue and profit growth in Q1 FY27, with robust performance in the pharmaceutical segment](https://longbridge.com/en/news/295639972.md)